Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

865 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
Bang Y, Yoo C, Lonardi S, Kim HD, Vivaldi C, Rimini M, Frassineti GL, Park SR, Rizzato MD, Ryu MH, Salani F, Rapposelli IG, Ryoo BY, Zagonel V, Massa V, Valgiusti M, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A. Bang Y, et al. Target Oncol. 2021 May;16(3):411-412. doi: 10.1007/s11523-021-00808-3. Target Oncol. 2021. PMID: 33738697 No abstract available.
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
Casadei-Gardini A, Scartozzi M, Tada T, Yoo C, Shimose S, Masi G, Lonardi S, Frassineti LG, Nicola S, Piscaglia F, Kumada T, Kim HD, Koga H, Vivaldi C, Soldà C, Hiraoka A, Bang Y, Atsukawa M, Torimura T, Tsuj K, Itobayashi E, Toyoda H, Fukunishi S, Rimassa L, Rimini M, Cascinu S, Cucchetti A. Casadei-Gardini A, et al. Among authors: bang y. Liver Int. 2021 Jun;41(6):1389-1397. doi: 10.1111/liv.14817. Epub 2021 Feb 20. Liver Int. 2021. PMID: 33547848
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
Bang Y, Yoo C, Lonardi S, Kim HD, Vivaldi C, Rimini M, Frassineti GL, Park SR, Rizzato MD, Ryu MH, Salani F, Rapposelli IG, Ryoo BY, Zagonel V, Massa V, Valgiusti M, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A. Bang Y, et al. Target Oncol. 2021 May;16(3):401-410. doi: 10.1007/s11523-021-00797-3. Epub 2021 Mar 1. Target Oncol. 2021. PMID: 33646487
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Casadei-Gardini A, Rimassa L, Rimini M, Yoo C, Ryoo BY, Lonardi S, Masi G, Kim HD, Vivaldi C, Ryu MH, Rizzato MD, Salani F, Bang Y, Pellino A, Catanese S, Burgio V, Cascinu S, Cucchetti A. Casadei-Gardini A, et al. Among authors: bang y. J Cancer Res Clin Oncol. 2021 Dec;147(12):3665-3671. doi: 10.1007/s00432-021-03602-w. Epub 2021 Mar 20. J Cancer Res Clin Oncol. 2021. PMID: 33745079
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib.
Rimini M, Yoo C, Lonardi S, Masi G, Piscaglia F, Kim HD, Rizzato MD, Salani F, Ielasi L, Forgione A, Bang Y, Soldà C, Catanese S, Sansone V, Ryu MH, Ryoo BY, Burgio V, Cucchetti A, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: bang y. Hepatol Res. 2021 Jul;51(7):796-802. doi: 10.1111/hepr.13669. Epub 2021 May 26. Hepatol Res. 2021. PMID: 34005839
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience.
Rimini M, Yoo C, Lonardi S, Masi G, Granito A, Bang Y, Rizzato MD, Vivaldi C, Ielasi L, Kim HD, Bergamo F, Salani F, Leoni S, Ryoo BY, Ryoo MH, Burgio V, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: bang y. Target Oncol. 2021 Sep;16(5):653-661. doi: 10.1007/s11523-021-00834-1. Epub 2021 Sep 7. Target Oncol. 2021. PMID: 34491510
865 results